When you browse the ADMA Biologics Web site your personal information is not revealed to us. Details such as your name and e-mail address remain anonymous. As usual with virtually all web pages, the only initial information recorded is your IP address, which helps us to administer our Web site and identify broad demographic information, such as your browser type and geographic location.
ADMA Biologics collects personally identifiable information, such as names, addresses, e-mail addresses and the like, only when voluntarily provided by a Web site user. ADMA Biologics does not want to receive confidential, proprietary or personal medical information through Web site communications.
Any communication with ADMA Biologics Web site or any other e-mail transmission to ADMA Biologics on this Web site is non-confidential. ADMA Biologics has no obligation to refrain from reproducing, publishing or otherwise using third party information for any purpose, and ADMA Biologics may use the content of any such communication, including any ideas or know how disclosed therein for ADMA Biologics’ own commercial purposes. Whoever transmits any communication to this Web site or otherwise to ADMA Biologics is solely responsible for its accuracy and completeness. This site is intended to provide a service to users.
All rights not expressly granted herein are reserved to ADMA Biologics.
Important Safety Information for Nabi-HB®
Individuals known to have had an anaphylactic or severe systemic reaction to human globulin should not receive Nabi-HB® [Hepatitis B Immune Globulin (Human)] or any other human immune globulin. Individuals who are deficient in IgA have the potential to develop antibodies against IgA and anaphylactic reactions.
In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, Nabi-HB should be given only if the expected benefits outweigh the potential risks.
Nabi-HB is made from human plasma. Products made from human plasma may carry a risk of transmitting infectious agents (e.g., viruses) and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
Nabi-HB [Hepatitis B Immune Globulin (Human)], must be administered only intramuscularly for post-exposure prophylaxis.
Vaccination with live virus vaccines (e.g., MMR) should be deferred until approximately three months after administration of Nabi-HB.
The most common adverse reactions associated with Nabi-HB in clinical trials were erythema and ache at the injection site as well as systemic reactions such as headache, myalgia, malaise, nausea and vomiting. No anaphylactic reactions with Nabi-HB have been reported.
Please see the full Prescribing Information for Nabi-HB [Hepatitis B Immune Globulin (Human)].
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.